SGMO

Sangamo Therapeutics Inc

0.72

-0.03-3.77%

After Hours: 0.7222 -0.00 -0.11%19:54 09/06 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE0.7500/0.7513

TODAY RANGE0.7011-0.7706

VOL3.48M

MARKET CAP150.54M

52 WEEK RANGE0.2911-1.480

AVG VOL (3M)14.67M

% TURNOVER1.67%

TURNOVER--

P/E (TTM)-0.5252

% RANGE9.25%

EPS(TTM)-1.3766

P/E(FORWARD)-1.3266

P/B6.35

BVPS0.1138

DIVIDEND--

P/S0.7308

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP146.52M

SHARES OUTSTANDING208.22M

NEXT EARNINGS10/30-11/04

FREE FLOAT202.65M

LOT SIZE1

EX-DIV DATE--

News

Press Releases

Financial Reports

Profile

Latest

Popular

Dow Jones·08/22 13:13
Sangamo Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.
TipRanks·08/22 10:17
Strong Buy Recommendation for Sangamo Biosciences Amidst Strategic Partnerships and Promising Gene Therapy Advancements
TipRanks·08/08 09:41
3 Penny Stocks to Watch Now, 8/8/24
TipRanks·08/07 12:20
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pennant Group (PNTG), Merus (MRUS) and Sangamo Biosciences (SGMO)
TipRanks·08/07 11:17
RBC Capital Remains a Hold on Sangamo Biosciences (SGMO)
TipRanks·08/07 11:02
Sangamo Biosciences: Hold Rating Amid Financial Challenges and Clinical Progress
TipRanks·08/07 07:50
Barclays Sticks to Their Buy Rating for Sangamo Biosciences (SGMO)
TipRanks·08/07 02:45
Strategic Partnerships and Clinical Success: A Buy Rating for Sangamo Biosciences
Reuters·08/06 22:01
Sangamo Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
NASDAQ·08/06 21:35
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates
Dow Jones·08/06 20:43
*Sangamo Expects to Get $50 M in Near-Term Upfront License Fees and Milestone Payments >SGMO
Dow Jones·08/06 20:43
*Sangamo Eligible to Earn Up to $1.9 B in Milestone Payments, Plus Tiered Royalties on Net Sales >SGMO
Seeking Alpha·08/06 20:38
Sangamo Therapeutics GAAP EPS of -$0.18 misses by $0.03, revenue of $0.3M misses by $7.96M
Reuters·08/06 20:01
SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND SECOND QUARTER 2024 FINANCIAL RESULTS
Dow Jones·08/06 20:01
Press Release: Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results

Same Industry

Name/Symbol

Change%

Price

Sangamo Therapeutics Inc

SGMO

-3.77%

0.7230

Regeneron Pharmaceuticals

REGN

-1.66%

First Wave Biopharma Inc

ENTO

-2.30%

0.3950

BIONTECH

BNTX

-0.23%

89.94

United Therapeutics Corp.

UTHR

-1.25%

345.63

Vertex Pharmaceuticals Inc

VRTX

-0.12%

468.00

Siga Technologie

SIGA

-3.26%

7.71

Moderna

MRNA

-0.75%

72.89

Charles Riv Labs Intl Inc

CRL

-1.69%

187.96

Medpace Holdings

MEDP

-3.36%

335.74

Talphera Inc

TLPH

-1.98%

0.9900

ICON PLC

ICLR

-1.78%

302.52

China Biologic

CBPO

119.99

Iqvia Hldgs Inc

IQV

-2.04%

243.07

MOLECULAR PARTNERS AG

MOLN

-4.75%

5.51

Arcturus Therape

ARCT

-0.69%

18.69

Gilead Sciences Inc

GILD

-0.06%

78.72

PRA Health

PRAH

165.21

Incyte Corp

INCY

-2.70%

61.26

Aptevo Therapeutics Inc

APVO

-2.63%

0.3299

Biospecifics

BSTC

+0.15%

88.53

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.